Kadimastem Receives Grant for a Total Budget of $3.1 million from the Israeli Innovation Authority
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
- Dec 13, 2021
- 4 min
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority
- Nov 25, 2021
- 5 min
ILEX Medical to Invest 10 million NIS ($3.2 million)
- Nov 15, 2021
- 1 min
We rang the TASE bell today!
- Oct 25, 2021
- 4 min
Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement
- Oct 12, 2021
- 3 min
Successful Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes
- Jul 21, 2021
- 3 min
Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan
- May 11, 2021
- 3 min
Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article
- Apr 26, 2021
- 3 min
Kadimastem Raises NIS 22.3 Million ($6.8 Million)
- Mar 9, 2021
- 3 min
Kadimastem Granted a Patent in Israel for the Treatment of ALS
- Jan 31, 2021
- 5 min
Kadimastem Announces Executive Management Changes
- Dec 15, 2020
- 5 min
Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS
- Aug 3, 2020
- 7 min
Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in
- Jan 2, 2020
- 7 min
Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
- Dec 23, 2019
- 4 min
Kadimastem Announces the Completion of Treatment for Cohort B
- Nov 19, 2019
- 4 min
Successful Preclinical results of our Cell Therapy Treatment for Insulin-Dependent Diabetes
- Nov 17, 2019
- 4 min
Kadimastem to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol
- Nov 11, 2019
- 3 min
Kadimastem to Present at the 7th International Stem Cell Meeting, in Tel-Aviv
- Sep 24, 2019
- 5 min
Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
- May 20, 2019
- 2 min
Kadimastem Announces Leadership Changes